A phase II, double-blind, placebo controlled, randomised study to assess the efficacy and safety of 2 doses of ZACTIMA (ZD6474) in combination with FOLFIRI vs. FOLFIRI alone for the treatment of colorectal cancer in patients who have failed therapy with a
Read time: 1 mins
Last updated:21st Feb 2008
The primary objective of this study is to assess the efficacy of ZD6474 (100 mg and 300 mg) in combination with FOLFIRI versus FOLFIRI alone for the treatment of patients with colorectal cancer that have failed prior treatment with oxaliplatin and a fluoropyrimidine by assessment of disease progression.
|Study start date||2008-02-21|